MedTrace Logo

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

NCT03593681 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-01-20

Study results available
· View outcomes & findings →

Summary

Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.

Conditions

  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Ovarian Neoplasms
  • Ovary Cancer
  • Fallopian Tube Neoplasms
  • Fallopian Tube Adenocarcinoma
  • High Grade Serous Carcinoma
  • Peritoneal Carcinoma
  • Peritoneal Neoplasms
  • Adnexal Mass
  • Ovarian Diseases

Interventions

DEVICE

Hysteroscopic cell sampling of the fallopian tube

Hysteroscopic fallopian tube biopsy

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Ted L Anderson, MD,PhD,FACOG · Vanderbilt University Medical Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-27
Primary Completion
2020-02-14
Completion
2020-02-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03593681 on ClinicalTrials.gov